Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kazem, R.
Right arrow Articles by Templeton, A.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kazem, R.
Right arrow Articles by Templeton, A.A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 11, No. 12, pp. 2585-2590, 1996
© 1996 European Society of Human Reproduction and Embryology


research-article

Endocrinology: Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women

R. Kazem1, L.E. Messinis2,5, P. Fowler1, N.P. Groome3, P.G. Knight4 and A.A. Templeton1

1Department of Obstetrics and Gynaecology, University of Aberdeen UK 2Department of Obstetrics and Gynaecology, University of Thessalia Larissa, Greece 3School of Biological and Molecular Sciences, Oxford Brookes University Oxford 4School of Animal and Microbial Sciences, The University of Reading UK

Correspondence: 5To whom correspondence should be addressed

Mifepristone interrupts folliculogenesis in women but the mechanism is not clear. Previous studies have investigated the effect of this compound on gonadotrophin secretion and have provided conflicting results. To study further the effect of mifepristone on basal and gonadotrophin-releasing hormone (GnRH)-induced gonadotrophin secretion, 12 normally ovulating women were investigated during two consecutive menstrual cycles, comprising an untreated cycle (control) and a cycle treated with mifepristone. All women were treated with mifepristone on days 2–8 at the dose of 100 mg (group 1, eight women) or 10 mg per day (group 2, six women). Two women were treated with both regimens in two different cycles. On day 8 of both cycles, the women received two GnRH pulses of 10 µg each 2 h apart. Blood samples in relation to the first GnRH pulse were taken at –15, 0, 30, 60, 120, 150, 180 and 240 min. In group 1, the increase in luteinizing hormone ({delta}LH) in response to GnRH was significantly attenuated from 30 to 180 min, while the increase in follicle stimulating hormone ({delta}FSH) was attenuated only in response to the second GnRH pulse. No significant decrease in {delta}LH and {delta}FSH response to GnRH was seen during treatment with the 10 mg dose (group 2). In group 1, serum oestradiol and inhibin-A concentrations after day 8 were lower than in the control cycles and the LH peak was postponed by 7 days on average. Basal LH values increased significantly on day 8 in both groups, while FSH values did not change significantly compared with the control cycles. A significant increase in serum progesterone and cortisol values occurred during the treatment only in group 1. Mid-luteal values of inhibin-A were significantly lower in cycles treated with 100 mg mifepristone than in the control cycles. We conclude that the disruption of folliculogenesis by mifepristone cannot be explained by a decrease in basal FSH concentrations during the critical period of follicle recruitment and selection. It is possible that mifepristone exerts its effect at the level of the ovary. It is also suggested that progesterone during the follicular phase of the cycle may participate in the control of the self-priming action of GnRH on the pituitary.

Key words: folliculogenesis/gonadotrophin-releasing hormone/mifepristone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
Y. Tenenbaum-Rakover, M. Commenges-Ducos, A. Iovane, C. Aumas, O. Admoni, and N. de Roux
Neuroendocrine Phenotype Analysis in Five Patients with Isolated Hypogonadotropic Hypogonadism due to a L102P Inactivating Mutation of GPR54
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1137 - 1144.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
I. E. Messinis
Ovarian feedback, mechanism of action and possible clinical implications
Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Dafopoulos, I. Mademtzis, P. Vanakara, A. Kallitsaris, G. Stamatiou, C. Kotsovassilis, and I. E. Messinis
Evidence That Termination of the Estradiol-Induced Luteinizing Hormone Surge in Women Is Regulated by Ovarian Factors
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 641 - 645.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Dafopoulos, C.G. Kotsovassilis, S. Milingos, A. Kallitsaris, G. Galazios, E. Zintzaras, P. Sotiros, and I.E. Messinis
Changes in pituitary sensitivity to GnRH in estrogen-treated post-menopausal women: evidence that gonadotrophin surge attenuating factor plays a physiological role
Hum. Reprod., September 1, 2004; 19(9): 1985 - 1992.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.